Click here to search courses using NAPNAP's previous Course Catalog layout.

Title
Category
Credits
Event date
Cost
  • Primary Care
  • Pharmacology CE
  • Contact hours
$20.00
1.0 NAPNAP Contact Hour of which 0.25 contain pharmacology content. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $10 for NAPNAP Members. For non-members, this continuing education activity rate is $20. The presenters will address four chronic health conditions that can present challenges to the pediatric-focused NP in a primary care clinic: congenital heart disease, chronic renal failure, post traumatic brain injury and cystic fibrosis. Clinical experts will present the primary care needs of children with medical complexity, which may be different from other children coming to your clinic, including vaccination schedules, medications, developmental considerations and when to call the specialist.
  • Primary Care
  • Pharmacology CE
  • Contact hours
$20.00
1.0 NAPNAP Contact Hour. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $10 for NAPNAP Members. For non- members, this continuing education activity rate is $20. This presentation will cover the latest research, new medications and updated practice guidelines in pediatric migraine management as well as how to evaluate and use the current evidence in practice.
  • Primary Care
  • FREE for Members
  • Pharmacology CE
  • Contact hours
$10.00
1.0 NAPNAP contact hour, 1.0 pharmacology contact hour. This continuing education activity is offered free to NAPNAP Members. For non-members, this continuing education activity rate is $10. Before 2018, there were no U.S. Food and Drug Administration approved medications for managing seizures in Dravet syndrome (DS). Common agents used in the antiepileptic drug regimens of patients with DS included clobazam, valproic acid, topiramate, and levetiracetam, among others; however, these agents alone rarely provide adequate seizure control. Management of seizures in DS changed in recent years with the approval of cannabidiol and stiripentol in 2018 and fenfluramine in 2020. This continuing education article summarizes available efficacy and safety data involving cannabidiol, stiripentol, and fenfluramine and provides a practical review of dosing strategies, pharmacokinetics, and monitoring interventions relevant to their use. J Pediatr Health Care. (2022) 36, 479−488
  • Primary Care
  • Pharmacology CE
  • Contact hours
$20.00
1.0 NAPNAP Pharmacology Contact Hour. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $10 for NAPNAP Members. For non- members, this continuing education activity rate is $20. Penicillin allergy, the most commonly reported allergy in a pediatric patient, is associated with increases in cost of care, hospitalization and morbidity, as well as contributing to antibiotic resistance. However, 95% of patients labeled with a penicillin allergy do not have a true allergy. The Centers for Disease Control & Prevention has identified improper use of antibiotics to be an important factor that must be addressed for both patient safety and public health. This presentation will identify high-risk symptoms of allergy, differentiate between adverse reactions, IgE-mediated allergic reaction and delayed T-cell reactions, as well as discuss appropriate testing for penicillin allergy. Additionally, the presenter will address alternative antibiotics that can be used until a formal allergy evaluation can be completed.

Pages